Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000629005 | SCV000059538 | pathogenic | Hypertrophic cardiomyopathy | 2022-02-07 | criteria provided, single submitter | clinical testing | The p.Ala1379Thr variant in MYH7 has been reported in >10 families with HCM and segregated with disease in >15 affected relatives (Blair 2002, Richard 2003, Zou 2013, Burns 2016, Walsh 2017, LMM data). It has also been identified in 1/35440 Latino chromosomes in gnomAD (http://gnomad.broadinstitute.org) and has been reported in ClinVar (Variation ID 42993). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, this variant meets criteria to be classified as pathogenic for HCM in an autosomal dominant manner. ACMG/AMP criteria applied: PS4, PP1_Strong, PM2_Supporting, PP3. |
Gene |
RCV000505712 | SCV000208572 | pathogenic | not provided | 2024-09-19 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25961035, 28166811, 30466861, 23283745, 16918501, 11861410, 22199023, 21310275, 12707239, 27532257, 27247418, 28790153, 28615295, 33631351, 33673806, 32894683, 33087929, 36252119, 36264615, 37498360, 37652022, 36243179, 35935646, 34076677, 15136674, 12951062, 37079208, 11861413) |
Agnes Ginges Centre for Molecular Cardiology, |
RCV000162337 | SCV000212637 | pathogenic | Hypertrophic cardiomyopathy 1 | 2018-08-23 | criteria provided, single submitter | research | MYH7 Ala1379Thr has previously been identified in multple HCM cases (Walsh R et al., 2017; Zou Y et al., 2013; Richard P et al., 2003; Blair E et al., 2002). Familial analysis by Blair E. et al. (2002) demonstrated strong segregation of this variant with disease phenotype. We have detected this variant in 4 unrelated HCM families, 3 of which were reported previously (Ingles J et al., 2017; Burns et al., 2017) and segregated to an additional 3 affected family members in one family. Furthermore, this variant is absent in both the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/) and 1000 genomes project (http://www.1000genomes.org/). In silico tools SIFT, MutationTaster and PolyPhen-2 predict that the variant is deleterious. More specifically, a tool designed to predict the effects of missense variants in HCM genes (Jordan DM, et al., 2011), predicts this MYH7 Ala1379Thr variant to be "Pathogenic". Based on the adapted ACMG guidelines (Kelly MA, et al., 2018), this variant has been identified in more than 10 unrelated probands (PS4_Strong), has strong segregation data (PP1_Strong), is rare in the general population (PM2) and in silico tools predict that it is deleterious (PP3), therefore we classify MYH7 Ala1379Thr as 'pathogenic'. |
Center for Medical Genetics Ghent, |
RCV000162337 | SCV000299237 | likely pathogenic | Hypertrophic cardiomyopathy 1 | 2016-02-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000619392 | SCV000737001 | pathogenic | Cardiovascular phenotype | 2023-01-25 | criteria provided, single submitter | clinical testing | The p.A1379T pathogenic mutation (also known as c.4135G>A), located in coding exon 28 of the MYH7 gene, results from a G to A substitution at nucleotide position 4135. The alanine at codon 1379 is replaced by threonine, an amino acid with some similar properties. This variant was reported to segregate with hypertrophic cardiomyopathy (HCM) or related features in multiple individuals across three HCM proband-identified families, and has also been detected in additional HCM cohorts (Blair E et al. Circ Res. 2002;90:263-9; Zou Y et al. Mol Biol Rep. 2013;40:3969-76; Richard P et al. Circulation. 2003;107:2227-32; Walsh R et al. Genet. Med., 2017 Feb;19:192-203). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV000629005 | SCV000749915 | pathogenic | Hypertrophic cardiomyopathy | 2024-12-23 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 1379 of the MYH7 protein (p.Ala1379Thr). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individuals with hypertrophic cardiomyopathy (PMID: 11861413, 12707239, 23283745, 27247418, 27532257, 28790153). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 42993). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt MYH7 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000035887 | SCV001337987 | pathogenic | Primary familial hypertrophic cardiomyopathy | 2020-01-27 | criteria provided, single submitter | clinical testing | Variant summary: MYH7 c.4135G>A (p.Ala1379Thr) results in a non-conservative amino acid change located in the Myosin tail domain (IPR002928) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251464 control chromosomes (gnomAD). c.4135G>A has been reported in the literature in multiple individuals affected with Hypertrophic Cardiomyopathy (Richard_2003, Blair_2002, Ross_2017). Blair_2002 reported that this variant segregated with disease in three unrelated families and was not present in 200 control chromosomes. These data indicate that the variant is very likely to be associated with disease. At least one publication, Flashman_2007, reports this variant has no effect on interaction with C10 of cMyBP-C. Four ClinVar submitters (evaluation after 2014) cite the variant as pathogenic (3x) and likely pathogenic (1x). Based on the evidence outlined above, the variant was classified as pathogenic. |
CHEO Genetics Diagnostic Laboratory, |
RCV003149622 | SCV003838748 | pathogenic | Cardiomyopathy | 2021-08-20 | criteria provided, single submitter | clinical testing | |
Clinical Genetics Laboratory, |
RCV000505712 | SCV005199388 | pathogenic | not provided | 2022-07-13 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000629005 | SCV005430832 | pathogenic | Hypertrophic cardiomyopathy | 2024-09-27 | criteria provided, single submitter | clinical testing | The c.4135G>A (p.Ala1379Thr) variant in MYH7 gene, that encodes for myosin heavy chain 7, has been identified in multiple unrelated individuals (>18) affected with hypertrophic cardiomyopathy (HCM) and segregated with disease in 15 individuals in three unrelated families (PMID: 28790153, 12707239, 23283745, 27532257,11861413). Computational prediction tools suggest that the p.Ala1379Thr variant may have deleterious effect on the protein function (REVEL score: 0.773). This variant is rare (3/1613426 chromosomes; 0.0001859%) in the general population database, gnomAD (v4.1.0) and interpreted as likely pathogenic/pathogenic by multiple submitters in the ClinVar database (ID: 42993). Therefore, the c.4135G>A (p.Ala1379Thr) variant in the MYH7 gene is classified as pathogenic. |
Institute of Human Genetics, |
RCV000162337 | SCV005627513 | pathogenic | Hypertrophic cardiomyopathy 1 | 2024-12-11 | criteria provided, single submitter | clinical testing | Criteria applied: PP1_STR,PS4_MOD,PM5,PM2_SUP,PP3 |
Blueprint Genetics | RCV000035887 | SCV000188802 | likely pathogenic | Primary familial hypertrophic cardiomyopathy | 2013-10-16 | no assertion criteria provided | clinical testing |